<DOC>
	<DOCNO>NCT01424280</DOCNO>
	<brief_summary>The purpose study assess bronchodilator effect single dose administration GSK1440115 population mild moderate asthmatic patient .</brief_summary>
	<brief_title>Single Dose Study GSK1440115 Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Capable give write informed consent , include compliance requirement restriction list consent form . 2 . Male female 18 65 year age , inclusive , time signing informed consent . 3 . Male patient female partner childbearing potential must prior vasectomy agree use adequate contraception time first dose study drug three month last dose study drug . 4 . A female patient eligible participate : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/mL estradiol &lt; 40 pg/mL ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method define protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . For form HRT , least two four week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . 2 . Childbearing potential , negative serum pregnancy test Screening Period , agree use adequate contraception Screening four week last dose study drug . 5 . BMI within range 1932 kg/m2 ( inclusive ) . 6 . Documented history bronchial asthma British Thoracic Society guideline step 13 , diagnose least 3 month prior Screening visit . . Patient fixed regimen least 4 week prior Screening . The following asthma medication permit : . Inhaled corticosteroid ( ICS ) per day use : &lt; =800mcg Beclomethasone Dipropionate budesonide , 320mcg ciclesonide 500mcg Fluticasone propionate equivalent dos . ii . Intermittent shortacting inhaled beta2 agonist therapy ( SABA ) . A minimum 8 hour washout SABA require prior Screening study methacholine challenge test FEV1 assessment . iii . Longacting inhaled beta2 agonist ( LABA ) therapy permit study . If deem appropriate investigator , patient usually manage LABA switch SABA order comply requirement washout . A minimum 24 hour washout last dose LABA require prior Screening methacholine challenge test FEV1 assessment . iv . Therapy montelukast allow provided administration separate least 12 hour study drug dosing ( see Section 9 ) . 7 . Best FEV1 &gt; 70 % predict normal value Screening . 8 . Hyperresponsive methacholine baseline methacholine PC20 &lt; = 4 mg/mL . 9 . Increase PC20 least 2 dilution compare baseline presence inhale betaagonist response methacholine challenge . 10 . Patients currently nonsmoker use inhaled tobacco product previous 6 month prior first dose study drug . 11 . Average QTcF &lt; 450 msec ; QTc &lt; 480 msec patient Bundle Branch Block . 12 . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 1 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Screening . 2 . A positive test HIV antibody . 3 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 4 . A positive prestudy drug/alcohol screen . 5 . History regular alcohol consumption within 6 month study define : History regular alcohol intake ( average weekly intake &gt; 21 unit male &gt; 14 unit females One unit equivalent 270 mL full strength beer , 470 mL light beer , 30 mL spirit 100 mL wine . 6 . History chronic medical disease investigator opinion may affect outcome study include interpretation safety data . This may include , limited , malignancy , cardiovascular , hepatic , renal , hematological , neurological , thyroid disease , endocrine disease , , pulmonary disease . Examples specific exclusion include : History heart attack stroke within past 3 month . Presence know aortic aneurysm . Epilepsy . COPD , pulmonary fibrosis , bronchiectasis Peptic ulcer disease . Urinary tract obstruction . 7 . Clinically significant laboratory abnormality Screening . 8 . History uncontrolled hypertension persistent SBP &gt; 140 mmHg DBP &gt; 90mmHg Screening . 9 . History lifethreatening asthma ( asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure ) OR follow : Respiratory tract infection and/or asthma exacerbation within 4 week prior first dose study drug . Asthma exacerbation require hospitalization within 3 month prior Screening . Administration systemic steroid within 4 week Screening . 10 . Intake investigational product within either 30 day 5 half life ( whichever longer ) prior first dose study drug . 11 . History sensitivity study drug , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 12 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 13 . Lactating female . 14 . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior Screening . 15 . Current use prohibit medication require use prohibit medication study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>